melatonin has been researched along with Headache, Tension in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the differences in cortisol and melatonin concentrations between children with frequent episodic tension-type headache (FETTH) and healthy children." | 7.77 | Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children. ( Ambite-Quesada, S; Arroyo-Morales, M; Fernández-de-las-Peñas, C; Fernández-Mayoralas, DM; Linares-García-Valdecasas, R; Palomar-Gallego, MA; Rivas-Martínez, I, 2011) |
| "To investigate the differences in cortisol and melatonin concentrations between children with frequent episodic tension-type headache (FETTH) and healthy children." | 3.77 | Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children. ( Ambite-Quesada, S; Arroyo-Morales, M; Fernández-de-las-Peñas, C; Fernández-Mayoralas, DM; Linares-García-Valdecasas, R; Palomar-Gallego, MA; Rivas-Martínez, I, 2011) |
| "Migraine is one of the most severe and debilitating primary headache disorders." | 2.61 | Therapeutic role of melatonin in migraine prophylaxis: A systematic review. ( Long, R; Zhou, S; Zhu, Y, 2019) |
| "Models of sleep physiology and insomnia are discussed, along with the potential implications for the chronification of migraine and tension-type headache." | 2.48 | Chronic headaches and insomnia: working toward a biobehavioral model. ( Ong, JC; Park, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liampas, I | 1 |
| Siokas, V | 1 |
| Brotis, A | 1 |
| Mentis, AA | 1 |
| Aloizou, AM | 1 |
| Dastamani, M | 1 |
| Tsouris, Z | 1 |
| Lima, M | 1 |
| Dardiotis, E | 1 |
| Long, R | 1 |
| Zhu, Y | 1 |
| Zhou, S | 1 |
| Miano, S | 1 |
| Parisi, P | 1 |
| Pelliccia, A | 1 |
| Luchetti, A | 1 |
| Paolino, MC | 1 |
| Villa, MP | 1 |
| Rivas-Martínez, I | 1 |
| Ambite-Quesada, S | 1 |
| Fernández-de-las-Peñas, C | 1 |
| Arroyo-Morales, M | 1 |
| Fernández-Mayoralas, DM | 1 |
| Linares-García-Valdecasas, R | 1 |
| Palomar-Gallego, MA | 1 |
| Ong, JC | 1 |
| Park, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
3 reviews available for melatonin and Headache, Tension
| Article | Year |
|---|---|
Endogenous melatonin levels and therapeutic use of exogenous melatonin in tension type headache: A systematic review.
Topics: Adult; Analgesics; Case-Control Studies; Child; Humans; Melatonin; Tension-Type Headache | 2021 |
Therapeutic role of melatonin in migraine prophylaxis: A systematic review.
Topics: Central Nervous System Depressants; Humans; Melatonin; Migraine Disorders; Observational Studies as | 2019 |
Chronic headaches and insomnia: working toward a biobehavioral model.
Topics: Actigraphy; Adaptation, Psychological; Caffeine; Chronobiology Phenomena; Comorbidity; Headache Diso | 2012 |
1 trial available for melatonin and Headache, Tension
| Article | Year |
|---|---|
Melatonin to prevent migraine or tension-type headache in children.
Topics: Adolescent; Age Factors; Central Nervous System Depressants; Child; Consciousness Disorders; Female; | 2008 |
1 other study available for melatonin and Headache, Tension
| Article | Year |
|---|---|
Salivary cortisol and melatonin levels in children with frequent episodic tension-type headache do not differ from healthy children.
Topics: Case-Control Studies; Child; Depression; Female; Humans; Hydrocortisone; Male; Melatonin; Saliva; Te | 2011 |